Peter A. Hruskoci

Array ( [id] => 17399591 [patent_doc_number] => 20220041681 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-02-10 [patent_title] => GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY [patent_app_type] => utility [patent_app_number] => 17/412811 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28577 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => 0 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17412811 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18770843 [patent_doc_number] => 20230365643 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-16 [patent_title] => PEPTIDE, AND COSMETIC COMPOSITION AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 18/024819 [patent_app_country] => US [patent_app_date] => 2021-08-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8508 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18024819 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673078 [patent_doc_number] => 20230310551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => INSULIN RECEPTOR PARTIAL AGONISTS [patent_app_type] => utility [patent_app_number] => 18/041825 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30191 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17719087 [patent_doc_number] => 20220211806 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-07 [patent_title] => METHOD FOR PROMOTING BONE GROWTH USING ACTIVIN-ACTRIIA ANTAGONISTS [patent_app_type] => utility [patent_app_number] => 17/410175 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20030 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 33 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17410175 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19769990 [patent_doc_number] => 20250051416 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-02-13 [patent_title] => INSULIN RECEPTOR PARTIAL AGONISTS [patent_app_type] => utility [patent_app_number] => 18/041821 [patent_app_country] => US [patent_app_date] => 2021-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19329 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18041821 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20136211 [patent_doc_number] => 20250243255 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-07-31 [patent_title] => CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY [patent_app_type] => utility [patent_app_number] => 18/021712 [patent_app_country] => US [patent_app_date] => 2021-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18021712 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656256 [patent_doc_number] => 20230302148 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST [patent_app_type] => utility [patent_app_number] => 18/040869 [patent_app_country] => US [patent_app_date] => 2021-08-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18897 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 149 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18040869 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18752477 [patent_doc_number] => 20230355729 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => MULTIEPITOPE VACCINE FOR THE TREATMENT OF ALZHEIMER'S DISEASE [patent_app_type] => utility [patent_app_number] => 18/245532 [patent_app_country] => US [patent_app_date] => 2021-08-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15522 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -65 [patent_words_short_claim] => 36 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18245532 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18691012 [patent_doc_number] => 20230321197 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-12 [patent_title] => Polyphenolic Insulin [patent_app_type] => utility [patent_app_number] => 18/019576 [patent_app_country] => US [patent_app_date] => 2021-08-04 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12407 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019576 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17242003 [patent_doc_number] => 20210361746 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-25 [patent_title] => COMPOSITION AND METHOD FOR REDUCING HYPOGLYCEMIA EVENTS IN DIABETES TREATMENT [patent_app_type] => utility [patent_app_number] => 17/444381 [patent_app_country] => US [patent_app_date] => 2021-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21242 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -5 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17444381 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18675105 [patent_doc_number] => 20230312683 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => STABLE PHARMACEUTICAL PREPARATION [patent_app_type] => utility [patent_app_number] => 18/019020 [patent_app_country] => US [patent_app_date] => 2021-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17848 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -40 [patent_words_short_claim] => 21 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18019020 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19883114 [patent_doc_number] => 12268798 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-04-08 [patent_title] => Method for screening of unpleasant odor masking agents [patent_app_type] => utility [patent_app_number] => 17/443737 [patent_app_country] => US [patent_app_date] => 2021-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 6 [patent_figures_cnt] => 12 [patent_no_of_words] => 5101 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 84 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17443737 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18738051 [patent_doc_number] => 20230346961 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-02 [patent_title] => GLP-1 AND GIP RECEPTOR CO-AGONISTS [patent_app_type] => utility [patent_app_number] => 18/016947 [patent_app_country] => US [patent_app_date] => 2021-07-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13814 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -31 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016947 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597236 [patent_doc_number] => 20230272030 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => INSULIN-FC FUSION PROTEIN AND APPLICATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/016714 [patent_app_country] => US [patent_app_date] => 2021-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16018 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016714 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17214546 [patent_doc_number] => 20210347883 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-11-11 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING ISCHEMIC HEART DISEASE [patent_app_type] => utility [patent_app_number] => 17/378184 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12520 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 94 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17378184 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19380928 [patent_doc_number] => 20240270798 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-15 [patent_title] => COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER DISEASE OR METABOLIC SYNDROME, COMPRISING FLAGELLIN FUSION PROTEINS [patent_app_type] => utility [patent_app_number] => 18/032902 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8879 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18032902 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18673145 [patent_doc_number] => 20230310630 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-05 [patent_title] => THERAPEUTIC USE OF COMBINATION COMPRISING TRIPLE AGONISTIC LONG-ACTING CONJUGATE OR TRIPLE AGONIST [patent_app_type] => utility [patent_app_number] => 18/016145 [patent_app_country] => US [patent_app_date] => 2021-07-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 24553 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 490 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18016145 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17952460 [patent_doc_number] => 11478534 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2022-10-25 [patent_title] => Formulation and method of preparing zinc-charged insulin for oral administration [patent_app_type] => utility [patent_app_number] => 17/374317 [patent_app_country] => US [patent_app_date] => 2021-07-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 24 [patent_no_of_words] => 8863 [patent_no_of_claims] => 4 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 46 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17374317 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17312892 [patent_doc_number] => 20210401940 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2021-12-30 [patent_title] => ISOLATED INTERLEUKIN-34 POLYPEPTIDE FOR USE IN PREVENTING TRANSPLANT REJECTION AND TREATING AUTOIMMUNE DISEASES [patent_app_type] => utility [patent_app_number] => 17/371646 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20377 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17371646 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18753989 [patent_doc_number] => 20230357346 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-09 [patent_title] => FUSION PROTEIN INCLUDING GLUCAGON-LIKE PEPTIDE-1 AND INTERLEUKIN-1 RECEPTOR ANTAGONIST AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/004872 [patent_app_country] => US [patent_app_date] => 2021-07-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7135 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18004872 [rel_patent_id] =>[rel_patent_doc_number] =>)